Arca Biopharma Announces Gencaro Atrial Fibrillation Clinical Data Selected for Presentation at HFSA 2019 Scientific Meeting
September 11 2019 - 8:30AM
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company
applying a precision medicine approach to developing
genetically-targeted therapies for cardiovascular diseases, today
announced that Gencaro atrial fibrillation clinical data from the
GENETIC-AF Phase 2B trial have been selected for presentation at
the Heart Failure Society of America (HFSA) 2019 Annual Scientific
Meeting being held September 13-16 in Philadelphia. William
T. Abraham, MD, FACP, FACC, College of Medicine Distinguished
Professor, Division of Cardiovascular Medicine at The Ohio State
University Wexner Medical Center, will present the data.
“Bucindolol response appears to be greater in
heart failure patients with less severe left ventricular
dysfunction, a patient population with few therapeutic options for
AF prevention or heart failure,” commented Dr. Abraham, “These data
provide additional support for pharmacogenetic guided therapy with
bucindolol for the prevention of atrial fibrillation in patients
with heart failure We look forward to confirming these important
findings in the upcoming Phase 3 PRECISION‑AF trial.”
Abstract Number and Title:
1641, “Pharmacogenetic Guided Beta-blocker Therapy with Bucindolol
for the Prevention of Atrial Fibrillation/flutter in Heart Failure:
Relationship of Left Ventricular Ejection Fraction to Treatment
Effect”
Opening Reception and Poster Reception
I: Friday, September 13, 2019; 6:00 – 7:30 p.m.
ETPoster Reception II: Saturday, September 14,
2019; 6:00 – 7:30p.m. ET About ARCA biopharmaARCA
biopharma is dedicated to developing genetically-targeted therapies
for cardiovascular diseases through a precision medicine approach
to drug development. ARCA’s lead product candidate, GencaroTM
(bucindolol hydrochloride), is an investigational,
pharmacologically unique beta-blocker and mild vasodilator being
developed for the potential treatment of atrial fibrillation in
heart failure patients. ARCA has identified common genetic
variations that it believes predict individual patient response to
Gencaro, giving it the potential to be the first
genetically-targeted AF prevention treatment. The Gencaro
development program has been granted Fast Track designation by FDA.
ARCA is also developing AB171, a thiol-substituted isosorbide
mononitrate, as a potential genetically-targeted treatment for
heart failure and peripheral arterial disease (PAD). For more
information, please visit www.arcabio.com or follow the Company on
LinkedIn.
Safe Harbor Statement
This press release contains "forward-looking
statements" for purposes of the safe harbor provided by the Private
Securities Litigation Reform Act of 1995. These statements include,
but are not limited to, statements regarding the ability of ARCA’s
financial resources to support its operations through the end of
the first quarter of 2020, potential future development plans for
Gencaro, the expected features and characteristics of Gencaro or
AB171, including the potential for genetic variations to predict
individual patient response to Gencaro, Gencaro’s potential to
treat AF, AB171’s potential to treat HF or PAD, future treatment
options for patients with AF, and the potential for Gencaro to be
the first genetically-targeted AF prevention treatment. Such
statements are based on management's current expectations and
involve risks and uncertainties. Actual results and
performance could differ materially from those projected in the
forward-looking statements as a result of many factors, including,
without limitation, the risks and uncertainties associated with:
ARCA’s financial resources and whether they will be sufficient to
meet its business objectives and operational requirements; ARCA may
not be able to raise sufficient capital on acceptable terms, or at
all, to continue development of Gencaro or to otherwise continue
operations in the future; results of earlier clinical trials may
not be confirmed in future trials; the protection and market
exclusivity provided by ARCA’s intellectual property; risks related
to the drug discovery and the regulatory approval process; and, the
impact of competitive products and technological changes.
These and other factors are identified and described in more detail
in ARCA’s filings with the Securities and Exchange Commission,
including without limitation ARCA’s annual report on Form 10-K for
the year ended December 31, 2018, and subsequent filings. ARCA
disclaims any intent or obligation to update these forward-looking
statements.
Investor & Media
Contact:Derek Cole720.940.2163derek.cole@arcabio.com
ARCA Biopharma (NASDAQ:ABIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
ARCA Biopharma (NASDAQ:ABIO)
Historical Stock Chart
From Sep 2023 to Sep 2024